Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Psoriasis: full-pipeline trial registry
26 of 127 indexed Psoriasis trials are currently recruiting.
Corpus placement: #93 of 28,707 conditions by registered trial count.
127 US clinical trials · 26 currently recruiting · #93 of 28,707 conditions by registered trial count
Psoriasis: 127 US clinical trials tracked, 26 recruiting.
Psoriasis is the subject of 127 registered US clinical trials on ClinicalTrials.gov, 26 of them currently open to new participants. 50 are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 8 of these trials.
Enrollment posture brief
Registry condition psoriasis
OPEN 26 | RECR 20% | LATE 50 | EARLY 36 | RANK #93 | SPON 8
Volume-matched condition peers
Nearest open-share peer: Healthy (21% recruiting · 1,096 trials)
Psoriasis lists 26 open slots (20% of 127 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Psoriasis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Psoriasis is recruiting below its size-band peers.
26 of 127 indexed trials (20.5%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Psoriasis trials is spread across many organizations.
Bristol-Myers Squibb accounts for 8 of 127 trials (6.3%). 65 distinct sponsors appear on at least one study for this condition label.
-
Typical Psoriasis enrolment sits around 84 participants.
Median target enrolment is 84 among the 126 trials that report a genuine target (sentinel values excluded). 68 of those (54%) plan for fewer than 100 participants.
-
Psoriasis research is mostly interventional.
101 interventional and 26 observational studies make up this index (79.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
127 total, page 2 of 3
Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
Maruho North America
NCT01908595
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
Dr. Reddy's Laboratories Limited
NCT03421197
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Northwestern University
NCT00879944
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis
Primus Pharmaceuticals
NCT01947491
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
AbbVie
NCT04908475
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
AbbVie
NCT03478787
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Amgen
NCT03123471
Collaborative Connected Health (CCH) for PCORI
University of Southern California
NCT02358135
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
NCT01490632
Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis
Bristol-Myers Squibb
NCT02931838
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
Amgen
NCT01690299
An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L.
NCT02326298
Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
Bristol-Myers Squibb
NCT05065762
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
UCB Biopharma S.P.R.L.
NCT02326272
A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis
Incyte Corporation
NCT00778700
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
Bristol-Myers Squibb
NCT05701995
BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab
Boehringer Ingelheim
NCT02054481
A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis
Amgen
NCT04175613
Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy
Abbott
NCT00566722
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Akros Pharma
NCT03832738
A Study in Participants With Moderate to Severe Psoriasis
Eli Lilly and Company
NCT01107457
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
AbbVie
NCT04435600
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
Astellas Pharma
NCT01096862
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
Sun Pharmaceutical Industries
NCT01206660
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
AbbVie
NCT03875508
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients
University of Rochester
NCT02413801
Randomized Study of PH-10 for Psoriasis
Provectus Pharmaceuticals
NCT01247818
Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis
Bausch Health Americas
NCT03058744
Genetic Analysis of Pediatric Psoriasis
Northwestern University
NCT03768284
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
Elaine Husni
NCT05571696
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Janssen Research & Development
NCT02905331
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00563524
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
Hoffmann-La Roche
NCT00504270
Evaluation of Clinical Outcomes in an Online Teledermatology Model for the Management of Psoriasis
University of California, Davis
NCT00971477
Prevalence of Sleep Disturbances in Psoriasis
Wake Forest University Health Sciences
NCT00895375
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
Leon Kircik, M.D.
NCT01745133
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Northwestern University
NCT03791216
Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis
Promius Pharma
NCT01714544
Sleep, Circadian Rhythm & Skin Health
University Hospitals Cleveland Medical Center
NCT02457000
Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis
Pfizer
NCT01736696
An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants
Bristol-Myers Squibb
NCT03419910
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
Hangzhou Yirui Pharmaceutical Technology Co.
NCT05718921
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
Bristol-Myers Squibb
NCT03254784
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
University of Pennsylvania
NCT02187172
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Amgen
NCT02576678
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Sirtris, a GSK Company
NCT01154101
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
Boehringer Ingelheim
NCT00848055
Single Ascending Dose Study of PRX003 in Healthy Subjects
Prothena Biosciences Limited
NCT02458677
MIcrovascular dysfuNction In Moderate-severe Psoriasis
Marcelo F. Di Carli, MD, FACC
NCT04271540
The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment
University of California, San Francisco
NCT01511315
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 16 |
| Phase 3 | 26 |
| Phase 4 | 24 |
Top Sponsors
Named interventions
Most-linked intervention names on Psoriasis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Psoriasis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Psoriasis page
127 registered trials, 26 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 26 Psoriasis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Bristol-Myers Squibb sponsors the most Psoriasis trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Psoriasis condition card totals 127 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.